A Measure Of Function For People With Pain
The American Chronic Pain Association Quality of Life Scale looks at ability to function, rather than at pain alone. It can help people with pain and their health care team to evaluate and communicate the impact of pain on the basic activities of daily life. This information can provide a basis for more effective treatment and help to measure progress over time.
My Story: Drug Tests and Pain Contracts Violate Patient Rights – National Pain Report – August 28th, 2014 by Arianne Grand Gassaway
More good points from the comments on this article posted earlier:
There are many docs that use the contract as a way to threaten their patients into doing useless & even dangerous procedures like epidurals,that have hurt way more than in helps as only about 20% of pain patients get relief! Also about 60% of pain patients are made much worse after an epidural & will suffer for the rest of our lives!
NO doc would hold bp meds or insulin “hostage” (at least not right now anyway) & No pharmacy would turn them away w/o their meds; but why should it be any different with chronic pain patients? Don’t we deserve the same help & compassion as any other chronic patient? Yet, we are NOT as we are ALL assumed & treated like criminals & addicts, even when we are legitimate, verified, & completely compliant!
Trigger Point Injections for Headache Disorders: Expert Consensus Methodology and Narrative Review
To review the existing literature and describe a standardized methodology by expert consensus for the performance of trigger point injections (TPIs) in the treatment of headache disorders. Despite their widespread use, the efficacy, safety, and methodology of TPIs have not been reviewed specifically for headache disorders by expert consensus.
‘Migraine Head Box’ Chills Pain
Minnesota doctor has come up with a non-prescription, low-tech way of treating severe headache pain—immersing the back of the patient’s head in a basin of gradually cooling water.
the technique appeared to work for the majority of a group of 18 patients who came to the Hennepin County Medical Center in Minneapolis, MN, with severe headaches including migraines.
Pain: Hope Through Research: National Institute of Neurological Disorders and Stroke (NINDS)
This is an exhaustive primer on pain and pain treatment, and covers the latest scientific findings.
What is pain? The International Association for the Study of Pain defines it as: An unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage.
The Two Faces of Pain: Acute and Chronic
It is useful to distinguish between two basic types of pain, acute and chronic, and they differ greatly.
Nonarthritic Hip Joint Pain – Clinical Practice Guidelines Linked to the International Classifiation of Functioning, Disability and Health From the Orthopaedic Section of the American Physical Therapy Association
This thorough text gives detailed anatomical descriptions of all that is currently known about hip problems (in 16,000 words). You can download the “PDF plus” file, which has some section bookmarks from: http://www.jospt.org/doi/pdfplus/10.2519/jospt.2014.0302
The Orthopaedic Section of the American Physical Therapy Association (APTA) has an ongoing effort to create evidence-based practice guidelines for orthopaedic physical therapy management of patients with musculoskeletal impairments described in the World Health Organization’s International Classification of Functioning, Disability, and Health (ICF). The purpose of these clinical practice guidelines is to describe the peer-reviewed literature and make recommendations related to nonarthritic hip joint pain.
DEA Places Heavy Restrictions on Vicodin and Other Hydrocodone Combination Drugs; Gives Stakeholders 45 Days to Adjust – Policy and Medicine
The DEA’s decision to move HCPs (Hydrocodone Combination Producs) from Schedule III to Schedule II will impact practitioners who can prescribe drugs, but ultimately it will affect all industries involved in the manufacture, supply, and distribution of HCPs.
Rescheduling will also change the process required to order and transfer HCPs from a distributor to a pharmacy. For Schedule III drugs, DEA registrants could transfer HCPs through simple invoices. Now all orders must be submitted on the official DEA Form 222, and separately from the pharmacy’s usual bulk order of CIII-V drugs.
FDA approves new insomnia drug | Formulary Journal
FDA has approved suvorexant (Belsomra, Merck) for adults with insomnia who have difficulty falling asleep and/or staying asleep.
Belsomra is a highly selective antagonist for orexin receptors. Orexin is a neurotransmitter found in a specific part of the brain that can help keep a person awake. The mechanism by which Belsomra exerts its therapeutic effect is presumed to be through antagonism of orexin receptors.
Belsomra has a different mechanism of action from currently approved sleep medicines
Belsomra is expected to be available in late 2014 or early 2015, based on the assumption that the Drug Enforcement Administration (DEA) will issue a final decision on the scheduling for Belsomra by this time.
Recommended dose of Belsomra is 10 mg, taken no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening. The total dose should not exceed 20 mg once daily.
Medical cannabis laws linked to lower opioid overdose mortality | Formulary Journal
Medical marijuana laws are associated with significantly lower state-level opioid pain reliever mortality rates, according to a study published online August 25 in JAMA Internal Medicine.
“In clinical practice, we have seen many people with chronic pain who say that marijuana is the only thing that works for their pain, or even that they had tried prescription painkillers—such as Vicodin, Percocet, or OxyContin—but the only thing that works is marijuana,”
They found that between 1999 and 2010, medical marijuana laws were associated with about a 25% lower rate of prescription painkiller overdose deaths, on average, relative to the years before the law and trends in non-law states.
Zogenix: No Overdoses or Diversion Caused by Zohydro – National Pain Report
Six months after the introduction of Zohydro, there have been no confirmed cases of diversion, overdose or death caused by the controversial painkiller,
A wave of controversy has surrounded Zohydro – the first single ingredient hydrocodone painkiller sold in the U.S. — since its introduction in March. The people who thought the sky was going to fall once this drug was on the market, it obviously hasn’t happened.
“Will there be abuse and diversion? absolutely. The drug’s hydrocodone. But I truly think, and again I’m prejudiced because I belong to the Safe Use and Advisory Board, but they have a lot of things in place to identify and react to it.”
In August, company officials said nearly 15,000 prescriptions for Zohydro have been written by nearly 2,800 prescribers in the U.S. Galer says sales continue to grow.